| Name | SkinBioTherapeutics |
|---|---|
| Epic | SBTX |
| Isin | GB00BF33H870 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 10.63p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £24.02 | Debt ratio | n/a |
| Shares in issue | 202.26 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -156.71 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -1.72 | 52-week high / low | 7.25p / 29.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | SkinBioTherapeutics |
|---|---|
| Address | The Core, Bath Lane, Newcastle Helix, Newcastle upon Tyne, United Kingdom, NE4 5TF |
| Telephone | +44 191 495 7325 |
| Website | http://www.skinbiotherapeutics.com |
| Director | Position |
|---|---|
| Mr Stuart Ashman | CEO |
| Mr Manprit Singh Randhawa | CFO |
| Mr Danielle Bekker | Non-Executive Director |
| Mr Martin Braddock Hunt | Non-Executive Chairman |
| Dr Catherine Denise Prescott | Independent Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 30/06/23 | 30/06/22 | 30/06/21 |
| Intangible asssets and goodwill | 0.7 | 0.63 | 0.53 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.87 | 0.75 | 0.67 |
| Inventory / work in progress | 0.03 | 0.12 | n/a |
| Trade and other receivables | 0.19 | 0.14 | 0.45 |
| Cash and equivalents | 1.31 | 1.8 | 4.61 |
| Other current assets and asset held for resale | 0.18 | 0.27 | n/a |
| Total of all assets | 2.59 | 3.08 | 5.73 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 0.53 | 0.51 | 0.4 |
| Long term liabilities | 0.07 | 0.1 | 0.11 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.6 | 0.61 | 0.52 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 1.99 | 2.48 | 5.22 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 1.73 | 1.57 | 1.57 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -11.12 | -8.29 | -5.5 |
| Share premium account | 10.95 | 8.76 | 8.76 |
| Total equity | 1.99 | 2.48 | 5.22 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -3 | -2.98 | -1.5 |
| Pre-tax profit | -3.01 | -2.99 | -1.5 |